Sionna Therapeutics (SION) Change in Accured Expenses (2024 - 2026)

Sionna Therapeutics (SION) has 3 years of Change in Accured Expenses data on file, last reported at -$3.5 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 19.84% year-over-year to -$3.5 million; the trailing twelve-month figure through Mar 2026 stood at $2.8 million (up 558.25% YoY), and the FY2025 full-year result was $2.0 million, up 82.87% from the prior year.
• Change in Accured Expenses fell to -$3.5 million in Q1 2026, from $2.5 million in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $3.2 million in Q4 2024 to a low of -$4.3 million in Q1 2025.
• A 3-year average of -$45333.3 and a median of $1.4 million in 2024 frame the typical range for Change in Accured Expenses.
• Peak annual rise in Change in Accured Expenses reached 344.69% in 2025, while the deepest fall reached 64.76% in 2025.
• Tracing SION's Change in Accured Expenses over 3 years: stood at $3.2 million in 2024, then dropped by 21.49% to $2.5 million in 2025, then tumbled by 238.96% to -$3.5 million in 2026.
• Business Quant data shows SION's Change in Accured Expenses at -$3.5 million in Q1 2026, $2.5 million in Q4 2025, and $1.7 million in Q3 2025.